SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    Probiotics in SIBO: neither universal benefit nor universal harm is established

    Evidence about probiotics in small intestinal bacterial overgrowth is inconsistent. A 2025 gastroenterology position paper found limited support for routine use and emphasized differences among studies.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    The studies do not describe one uniform intervention

    The position paper identifies variation in strains, treatment duration, populations, diagnostic methods and symptom measurements. Some studies suggest benefit, but many are small or methodologically limited. [1]

    Trials that combine probiotics with antibiotics or several other interventions cannot isolate the contribution of the probiotic alone. A favorable result for the combination is not proof for each ingredient. [1]

    Do not diagnose SIBO from a supplement response

    The uncertainty does not support a blanket recommendation that everyone with suspected SIBO should take probiotics, or that every probiotic inevitably makes it worse. The exact preparation and clinical situation matter. [1]

    Bloating after a product is not, by itself, a diagnosis of bacterial overgrowth. Persistent symptoms warrant assessment rather than switching repeatedly among products on the assumption that one universal microbiome rule applies. [1]

    A combination trial cannot rank individual ingredients

    Imagine symptoms improve with an antibiotic plus a probiotic and dietary changes. Without an appropriate comparison, the improvement cannot be assigned entirely to the probiotic.

    Key distinctions — Probiotics in SIBO
    DetailInterpretation
    Strain and regimenVary among studies
    Combination treatmentDoes not isolate one component
    Routine probiotic useEvidence remains limited
    Probiotics in SIBO: neither universal benefit nor universal harm is established — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. DIAGNOSIS AND TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH: AN OFFICIAL POSITION PAPER FROM THE BRAZILIAN FEDERATION OF GASTROENTEROLOGY - PMC
      Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.